Novo Nordisk A/S Sponsored ADR logo

Novo Nordisk A/S Sponsored ADR (NOVA)

Market Closed
29 Jul, 20:00
XMUN XMUN
47. 00
-14.9
-24.07%
- Market Cap
48.26 P/E Ratio
2.05% Div Yield
1,107 Volume
0 Eps
61.9
Previous Close
Day Range
45.65 60
Year Range
45.65 125
Want to track NOVA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 7 days

Summary

NOVA closed today lower at €47, a decrease of 24.07% from yesterday's close, completing a monthly decrease of -20.74% or €12.3. Over the past 12 months, NOVA stock lost -44.18%.
NOVA pays dividends to its shareholders, with the most recent payment made on Apr 08, 2025. The next estimated payment will be in 3 months ago on Apr 08, 2025 for a total of €1.099.
The last earnings report, released on May 07, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Aug 06, 2025.
Novo Nordisk A/S Sponsored ADR has completed 5 stock splits, with the recent split occurring on Sep 20, 2023.
The company's stock is traded on 9 different exchanges and in various currencies, with the primary listing on NYSE (USD).

NOVA Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Novo Nordisk: Massive Overreaction Presents An Opportunity

Novo Nordisk: Massive Overreaction Presents An Opportunity

Novo Nordisk's sharp selloff is an overreaction; long-term fundamentals remain solid despite lowered guidance and a sudden CEO change. US market headwinds, competitive pressure from Eli Lilly and telehealth, and regulatory loopholes are weighing on near-term growth. Novo Nordisk boasts a robust pipeline with promising obesity and diabetes drugs, including oral Wegovy and next-generation therapies.

Seekingalpha | 7 hours ago
Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing

Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing

Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade, despite strong double-digit sales and profit growth. The market is concerned about headwinds for semaglutide (Wegovy/Ozempic), including supply issues, competition, and regulatory risks. Despite the selloff, I believe Novo remains undervalued given its dominant GLP-1 franchise, robust pipeline, and long-term growth potential.

Seekingalpha | 9 hours ago
Wegovy maker Novo's profit warning wipes out $70B in market value after shares plunge 30%

Wegovy maker Novo's profit warning wipes out $70B in market value after shares plunge 30%

Novo, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard Jorgensen.

Nypost | 9 hours ago

Novo Nordisk A/S Sponsored ADR Dividends

Novo Nordisk A/S Sponsored ADR logo
NOVA 3 months ago
Other
€0.98 Per Share
Novo Nordisk A/S Sponsored ADR logo
NOVA 11 months ago
Other
€0.44 Per Share
Novo Nordisk A/S Sponsored ADR logo
NOVA 22 Mar 2024
Other
€0.79 Per Share
Novo Nordisk A/S Sponsored ADR logo
NOVA 18 Aug 2023
Other
€0.37 Per Share
Novo Nordisk A/S Sponsored ADR logo
NOVA 24 Mar 2023
Other
€0.5 Per Share

Novo Nordisk A/S Sponsored ADR Earnings

6 Aug 2025 (In 1 week) Date
5.98
Cons. EPS
-
EPS
7 May 2025 Date
-
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
5 Feb 2025 Date
-
Cons. EPS
-
EPS
6 Nov 2024 Date
-
Cons. EPS
-
EPS
Novo Nordisk A/S Sponsored ADR logo
NOVA 3 months ago
Other
€0.98 Per Share
Novo Nordisk A/S Sponsored ADR logo
NOVA 11 months ago
Other
€0.44 Per Share
Novo Nordisk A/S Sponsored ADR logo
NOVA 22 Mar 2024
Other
€0.79 Per Share
Novo Nordisk A/S Sponsored ADR logo
NOVA 18 Aug 2023
Other
€0.37 Per Share
Novo Nordisk A/S Sponsored ADR logo
NOVA 24 Mar 2023
Other
€0.5 Per Share
6 Aug 2025 (In 1 week) Date
5.98
Cons. EPS
-
EPS
7 May 2025 Date
-
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
5 Feb 2025 Date
-
Cons. EPS
-
EPS
6 Nov 2024 Date
-
Cons. EPS
-
EPS

Novo Nordisk A/S Sponsored ADR (NOVA) FAQ

What is the stock price today?

The current price is €47.00.

On which exchange is it traded?

Novo Nordisk A/S Sponsored ADR is listed on NYSE.

What is its stock symbol?

The ticker symbol is NOVA.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 2.05%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 5.98.

When is the next earnings date?

The next earnings report will release on Aug 06, 2025.

Has Novo Nordisk A/S Sponsored ADR ever had a stock split?

Novo Nordisk A/S Sponsored ADR had 5 splits and the recent split was on Sep 20, 2023.

Novo Nordisk A/S Sponsored ADR Profile

Drug Manufacturers - General Industry
Healthcare Sector
Lars Fruergaard Jorgensen CEO
XMUN Exchange
US6701002056 ISIN
DK Country
77,406 Employees
31 Mar 2025 Last Dividend
20 Sep 2023 Last Split
- IPO Date

Overview

Novo Nordisk A/S is an established global pharmaceutical company with a heritage dating back to 1923. With its headquarters in Bagsvaerd, Denmark, the company has a widespread operational reach across Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and other international markets. Novo Nordisk is committed to discovering and developing innovative pharmaceutical products, focusing primarily on Diabetes and Obesity Care, and Rare Disease. The company has carved a niche for itself by not just being a manufacturer but also engaging in the research and development of new pharmaceutical products, ensuring they provide contemporary and efficient solutions to the healthcare challenges of today.

Products and Services

Novo Nordisk A/S offers a comprehensive range of healthcare products and solutions aimed at addressing some of the most challenging diseases. With a focus on quality and innovation, their offerings encompass:

  • Diabetes and Obesity Care: This segment includes products specifically designed to manage diabetes and obesity, along with related cardiovascular conditions and other emerging therapeutic areas. The company’s commitment to combating diabetes and obesity is reflected in its continuous pursuit of safer and more effective treatments.
  • Rare Disease: Novo Nordisk takes a targeted approach to rare diseases, focusing on rare blood disorders, rare endocrine disorders, and providing hormone replacement therapy. These specialized treatments are developed with the aim of addressing medical needs that are often underserved, demonstrating the company's dedication to all patients, regardless of the rarity of their condition.
  • Insulin Pens: The company produces a variety of insulin pens that are designed for ease of use, ensuring that patients can manage their condition with confidence and precision. These devices are a testament to Novo Nordisk’s focus on patient-centric innovations.
  • Growth Hormone Pens: These pens are part of the portfolio intended for patients requiring growth hormone therapy. They simplify the administration process, making treatment more accessible and manageable for patients.
  • Injection Needles: To complement their insulin and growth hormone pens, Novo Nordisk also supplies high-quality injection needles, designed for minimal discomfort and optimal medication delivery.
  • Smart Solutions for Diabetes: Innovating beyond conventional treatments, Novo Nordisk offers smart insulin pens and Dose Check, an insulin dose guidance application. These smart solutions enhance the treatment experience by integrating advanced technology with patient care, facilitating better management of diabetes.

Through a collaboration agreement with Aspen Pharmaceuticals, Novo Nordisk also ensures the production of insulin products, highlighting their commitment to making essential medications accessible. The company's enduring legacy and forward-looking approach have positioned it as a key player in the global pharmaceutical industry, dedicated to improving the lives of patients worldwide.

Contact Information

Address: Novo Alle 1
Phone: 45 44 44 88 88